Potential of genetically engineered monoclonal antibodies for cancer immunotherapy.
Reisfeld
R A
RA
Department of Immunology, Research Institute of Scripps Clinic, La Jolla, CA 92037.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic; D005732:Gangliosides / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D008546:Melanoma, Experimental / Q000276:immunology / Q000628:therapy; D051379:Mice / Q000235:genetics / Q000276:immunology; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009447:Neuroblastoma / Q000276:immunology / Q000628:therapy*; D015202:Protein Engineering; D013045:Species Specificity; D014018:Tissue Distribution; D014183:Transplantation, Heterologous
D000911:Antibodies, Monoclonal; D005732:Gangliosides; C019403:ganglioside, GD2